SPG
51
-12
GOOGL
54
6
PRGO
33
-4
DLTR
54
-5
CPB
40
-4
ALLE
60
-4
PNW
49
-6
NWSA
91
3
GE
77
2
KR
56
-4
NEE
62
12
NFLX
76
3
DGX
46
-2
EXPD
35
-2
SWKS
51
-5
QRVO
69
-2
CCI
15
-2
AAPL
53
3
NEM
53
-2
WY
28
-2
SPG
51
-12
GOOGL
54
6
PRGO
33
-4
DLTR
54
-5
CPB
40
-4
ALLE
60
-4
PNW
49
-6
NWSA
91
3
GE
77
2
KR
56
-4
NEE
62
12
NFLX
76
3
DGX
46
-2
EXPD
35
-2
SWKS
51
-5
QRVO
69
-2
CCI
15
-2
AAPL
53
3
NEM
53
-2
WY
28
-2
Financhill
Back

Esperion Therapeutics 10K Form

Sell
22

ESPR
Esperion Therapeutics

Last Price:
$0.73
Seasonality Move:
-3.5%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ESPR News And Ratings

See the #1 stock for the next 7 days that we like better than ESPR

ESPR Financial Statistics

Sales & Book Value

Annual Sales: $332.3M
Cash Flow: $-22.6M
Price / Cash Flow: 0
Annual Sales: $-2.17
Price / Book: 0

Profitability

EPS (TTM): -0.80000
Net Income (TTM): $-153.2M
Gross Margin: $263.7M
Return on Equity: 0%
Return on Assets: -44.87%

Esperion Therapeutics Earnings Forecast

Key Esperion Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 18 years for ESPR is 79.36%.
  • The Selling, General & Administrative Expenses for ESPR have been equal to 49.07% of Gross Profit Margin.
  • The Research & Development expenses have been 13.91% of Revenue.
  • The Net Earning history of ESPR is -15.57% of Total Revenues.
  • Per Share Earnings over the last 18 years have been positive in 7 years.

Esperion Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ESPR
CUSIP: 29664W
Website: esperion.com

Debt

Debt-to-Equity Ratio: -0.69
Current Ratio: 1.18
Quick Ratio: 0.72

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 277.64

ESPR Technical Analysis vs Fundamental Analysis

Sell
22
Esperion Therapeutics (ESPR) is a Sell

Is Esperion Therapeutics a Buy or a Sell?